ArticleInternational journal of clinical and experimental pathology2026
Pancreatic metastasis from colon adenocarcinoma: a case report.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic metastasis from colon adenocarcinoma is an exceedingly rare clinical entity. Here, we report a 65-year-old female who presented with a 1-month history of epigastric pain, abdominal distension, nausea, and vomiting. An initial abdominal computed tomography (CT) scan revealed a hypodense pancreatic mass accompanied by incomplete intestinal obstruction. Given the diagnostic uncertainty, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the pancreatic lesion and colonoscopic biopsy of the colon were performed. Histopathological and immunohistochemical analyses confirmed the pancreatic tumor as a metastatic tumor originating from primary colon adenocarcinoma. The patient was eventually transferred to the oncology department for further antitumor treatment. EUS-FNA, when paired with immunohistochemical profiling, is an indispensable tool for differentiating pancreatic metastases from primary pancreatic adenocarcinoma, thereby guiding appropriate oncologic management and reducing the risk of misdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.